Trials / Not Yet Recruiting
Not Yet RecruitingNCT07342244
Safety and Efficacy of CLL1 CAR-T Followed by Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
- Status
- Not Yet Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- Donghua Zhang · Academic / Other
- Sex
- All
- Age
- 18 Years – 78 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to evaluate whether an innovative combination therapy (CLL1 CAR-T sequential allogeneic hematopoietic stem cell transplantation) is safe, feasible and effective for the treatment of relapsed/refractory acute myeloid leukemia (R/R AML).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CLL1 CAR-T Cell Sequential Allogeneic Hematopoietic Stem Cell Transplantation | CLL1 CAR-T Cell Sequential Allogeneic Hematopoietic Stem Cell Transplantation |
Timeline
- Start date
- 2026-01-30
- Primary completion
- 2028-12-20
- Completion
- 2029-12-20
- First posted
- 2026-01-15
- Last updated
- 2026-01-15
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07342244. Inclusion in this directory is not an endorsement.